• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血糖控制和体重变化作为长期糖尿病患者胰腺癌早期标志物的潜力:一项病例对照研究。

The Potential of Glycemic Control and Body Weight Change as Early Markers for Pancreatic Cancer in Patients With Long-standing Diabetes Mellitus: A Case-Control Study.

作者信息

Mueller Alexandra M, Meier Christoph R, Jick Susan S, Schneider Cornelia

出版信息

Pancreas. 2018 Aug;47(7):807-815. doi: 10.1097/MPA.0000000000001085.

DOI:10.1097/MPA.0000000000001085
PMID:29975346
Abstract

OBJECTIVES

The aim of this study was to characterize the role of glycemic control and weight change as markers for pancreatic cancer (PaC) in patients with long-standing diabetes.

METHODS

We conducted case-control analyses in patients with long-standing diabetes (>2 years) in the United Kingdom-based Clinical Practice Research Datalink. Cases were patients with PaC matched to control subjects on variables including age, sex, and diabetes duration. We compared glycated hemoglobin (HbA1c) levels, blood glucose levels, and weight change before cancer detection (matched date) between cases and control subjects to assess associations between the potential markers and PaC.

RESULTS

Cases were more likely than control subjects to have high HbA1c levels. The adjusted odds ratio (aOR) was 4.94 (95% confidence interval [CI], 3.52-6.94) for HbA1c of 64.0 mmol/mol or greater compared with HbA1c of 47.5 mmol/mol or less within 6 months before cancer detection and within >1 to 2 years, 2.66 (95% CI, 2.00-3.54). Weight loss was also more common in cases, with an aOR of 15.40 (95% CI, 10.65-22.26) for loss of 15.0% body weight or greater compared with stable weight. The aOR for patients with both weight loss of 15.0% or greater and high HbA1c at 2 years or less before diagnosis was 60.97 (95% CI, 35.87-103.65), compared with patients with neither.

CONCLUSIONS

Poor glycemic control and weight loss, particularly in combination, may be useful early markers for PaC in patients with long-standing diabetes.

摘要

目的

本研究旨在明确血糖控制和体重变化作为长期糖尿病患者胰腺癌(PaC)标志物的作用。

方法

我们在英国临床实践研究数据链中对长期糖尿病(>2年)患者进行了病例对照分析。病例为胰腺癌患者,对照对象在年龄、性别和糖尿病病程等变量上与病例匹配。我们比较了病例组和对照组在癌症检测前(匹配日期)的糖化血红蛋白(HbA1c)水平、血糖水平和体重变化,以评估潜在标志物与胰腺癌之间的关联。

结果

病例组的HbA1c水平高于对照组。在癌症检测前6个月内且在>1至2年内,HbA1c为64.0 mmol/mol或更高与HbA1c为47.5 mmol/mol或更低相比,校正优势比(aOR)为4.94(95%置信区间[CI],3.52 - 6.94);在癌症检测前>1至2年内,aOR为2.66(95% CI,2.00 - 3.54)。体重减轻在病例组中也更常见,体重减轻15.0%或更多与体重稳定相比,aOR为15.40(95% CI,10.65 - 22.26)。诊断前2年或更短时间内体重减轻15.0%或更多且HbA1c高的患者与两者均无的患者相比,aOR为60.97(95% CI,35.87 - 103.65)。

结论

血糖控制不佳和体重减轻,尤其是两者同时出现,可能是长期糖尿病患者胰腺癌的有用早期标志物。

相似文献

1
The Potential of Glycemic Control and Body Weight Change as Early Markers for Pancreatic Cancer in Patients With Long-standing Diabetes Mellitus: A Case-Control Study.血糖控制和体重变化作为长期糖尿病患者胰腺癌早期标志物的潜力:一项病例对照研究。
Pancreas. 2018 Aug;47(7):807-815. doi: 10.1097/MPA.0000000000001085.
2
Weight change and blood glucose concentration as markers for pancreatic cancer in subjects with new-onset diabetes mellitus: A matched case-control study.体重变化和血糖浓度作为新发糖尿病患者胰腺癌的标志物:一项匹配病例对照研究。
Pancreatology. 2019 Jun;19(4):578-586. doi: 10.1016/j.pan.2019.03.006. Epub 2019 Mar 26.
3
Pattern of increasing HbA1c levels in patients with diabetes mellitus before clinical detection of pancreatic cancer - a population-based nationwide case-control study.糖尿病患者在胰腺癌临床检测之前糖化血红蛋白水平升高的模式——一项基于全国人群的病例对照研究。
Acta Oncol. 2015 Jul;54(7):986-92. doi: 10.3109/0284186X.2015.1006402. Epub 2015 Mar 3.
4
BMI and HbA1c are metabolic markers for pancreatic cancer: Matched case-control study using a UK primary care database.体重指数和糖化血红蛋白是胰腺癌的代谢标志物:使用英国初级保健数据库进行的匹配病例对照研究。
PLoS One. 2022 Oct 5;17(10):e0275369. doi: 10.1371/journal.pone.0275369. eCollection 2022.
5
Determinants of poor glycemic control among adult patients with type 2 diabetes mellitus in Jimma University Medical Center, Jimma zone, south west Ethiopia: a case control study.埃塞俄比亚西南部 Jimma 地区 Jimma 大学医学中心的 2 型糖尿病成年患者血糖控制不佳的决定因素:一项病例对照研究。
BMC Endocr Disord. 2019 Aug 29;19(1):91. doi: 10.1186/s12902-019-0421-0.
6
Effect of dose of behavioral weight loss treatment on glycemic control in adults with prediabetes.行为体重降低治疗剂量对糖尿病前期成年人血糖控制的影响。
BMJ Open Diabetes Res Care. 2019 May 28;7(1):e000653. doi: 10.1136/bmjdrc-2019-000653. eCollection 2019.
7
Glycemic Changes and Weight Loss Precede Pancreatic Ductal Adenocarcinoma by up to 3 Years in a Diverse Population.在一个多样化的人群中,血糖变化和体重减轻可先于胰腺导管腺癌发生长达 3 年。
Clin Gastroenterol Hepatol. 2022 May;20(5):1105-1111.e2. doi: 10.1016/j.cgh.2021.07.046. Epub 2021 Aug 3.
8
Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data.利用电子病历数据评价 2 型糖尿病患者起始抗糖尿病治疗后体重变化与血糖控制之间的关系。
Diabetes Res Clin Pract. 2014 Mar;103(3):402-11. doi: 10.1016/j.diabres.2013.12.038. Epub 2014 Jan 3.
9
Hemoglobin A Accurately Predicts Continuous Glucose Monitoring-Derived Average Glucose in Youth and Young Adults With Cystic Fibrosis.血红蛋白 A 能准确预测囊性纤维化青少年和年轻成人的连续血糖监测衍生平均血糖。
Diabetes Care. 2018 Jul;41(7):1406-1413. doi: 10.2337/dc17-2419. Epub 2018 Apr 19.
10
Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus.在英国初级保健环境中,与早期与晚期使用达格列净强化治疗相比,2 型糖尿病患者的血糖、体重和血压变化。
Diabetes Res Clin Pract. 2019 Sep;155:107791. doi: 10.1016/j.diabres.2019.107791. Epub 2019 Jul 17.

引用本文的文献

1
Pancreatic cancer is associated with medication changes prior to clinical diagnosis.胰腺癌与临床诊断前的药物变化有关。
Nat Commun. 2023 Apr 28;14(1):2437. doi: 10.1038/s41467-023-38088-2.
2
Diabetes and pancreatic cancer: Exploring the two-way traffic.糖尿病与胰腺癌:探索双向交通。
World J Gastroenterol. 2021 Aug 14;27(30):4939-4962. doi: 10.3748/wjg.v27.i30.4939.
3
Early Detection of Pancreatic Cancer: Opportunities and Challenges.早期胰腺癌检测:机遇与挑战。
Gastroenterology. 2019 May;156(7):2024-2040. doi: 10.1053/j.gastro.2019.01.259. Epub 2019 Feb 2.
4
Gene Therapy for Pancreatic Diseases: Current Status.基因治疗胰腺疾病:现状。
Int J Mol Sci. 2018 Oct 31;19(11):3415. doi: 10.3390/ijms19113415.